HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leiner

This article was originally published in The Tan Sheet

Executive Summary

Private labeler to begin shipping generic famotidine 10 mg, marketed under ANDA approval granted to Dr. Reddy's Labs, by Oct. 1. Dr. Reddy's ANDA 75-758 for J&J/Merck Pepcid AC equivalent received FDA clearance Aug. 17; Leiner currently markets generic ranitidine 75 mg (Pfizer/Warner-Lambert's Zantac 75) for Dr. Reddy's. Leiner joins Perrigo (marketing under a license from Teva) and Ivax in OTC generic famotidine market (1"The Tan Sheet" Aug. 6, In Brief)

You may also be interested in...



Dr. Reddy’s, Leiner Partnership Focusing On Switches

Dr. Reddy's Laboratories and Leiner Health Products are actively looking at potential Rx-to-OTC switch projects as they build on their partnership

Dr. Reddy’s Stakes Claim In U.S. OTC Market With Leiner Deal

Dr. Reddy's Laboratories' foothold in the U.S. OTC drug market appears ready for expansion after the firm signed an exclusive 15-year OTC product development and marketing agreement with Leiner Health Products

Famotidine, permethrin lotion ANDAs

Genpharm receives FDA clearance for famotidine 10 mg tablets (ANDA 75-674) Dec. 21, becoming fourth firm to gain approval for private label stomach remedy equivalent to J&J/Merck's Pepcid AC (1"The Tan Sheet" Aug. 27, 2001, In Brief). Clay-Park Labs' Permethrin Lotion 1% (ANDA 76-090) receives FDA approval Dec. 20 and is second generic version of Pfizer/Warner-Lambert's Nix pediculicide...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132110

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel